Application of SNX8 in diagnosis of glioblastoma

The invention belongs to the field of cancer diagnosis, particularly relates to application of SNX8 in diagnosis of glioblastoma, and more particularly relates to a reagent for measuring mRNA (messenger ribonucleic acid) or protein expression level of SNX8 and application of the reagent. The inventi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LIU JIA, DAI HONGSHUANG, DAI LIZHONG, HE XIANG, GAO TANGJIE, WU KANG, ZHANG YUYING
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PHYSICS PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention belongs to the field of cancer diagnosis, particularly relates to application of SNX8 in diagnosis of glioblastoma, and more particularly relates to a reagent for measuring mRNA (messenger ribonucleic acid) or protein expression level of SNX8 and application of the reagent. The invention provides a composition for detecting a cancer marker. The composition comprises a reagent for measuring the mRNA or protein expression level of SNX8. SNX8 expression is used as the identification capability of a glioma diagnostic marker and the judgment capability of glioma prognosis, the area AUC under the curve is displayed to be 0.954, and SNX8 has high specificity and high sensitivity when being used for glioma diagnosis. The method has important significance for clinically evaluating the prognosis of glioma patients. In the glioma elderly patients, the five-year lifetime of SNX8 with high expression is about 20%, and the five-year lifetime of SNX8 with low expression is about 70%-80%, which prompts that SNX